A study to explore the safety and clinical activity of GSK2857916 when given with pembrolizumab in study participants with relapsed/refractory multiple myeloma (DREAMM 4)

Trial Overview

Am I Eligible?

Participating US Centers

Medical College of Wisconsin
Froedtert Hospital

This center has not yet started accepting patients.

Milwaukee, WI


Winship Cancer Institute
Emory University

This center has not yet started accepting patients.

Atlanta, GA


Levine Cancer Institute
Atrium Health

This center has not yet started accepting patients.

Charlotte, NC


IU Simon Cancer Center
Indiana University

This center has not yet started accepting patients.

Indianapolis, IN


Mount Sinai Hospital
Tisch Cancer Institute

This center has not yet started accepting patients.

New York, NY

NOT ACCEPTING

This is an upcoming trial that has not yet started accepting patients.

Add this trial to your favorites and we'll notify you when this trial begins accepting patients.



Additional Information
Trial Phase

Phase 2

Trial Enrollment

40 sparks required

Trial Sponsors
  • GlaxoSmithKline
Trial Identifiers

Need Help?

(888) 828-2206

Weekdays 9am - 5pm EST

;